the efficacy of a respiratory stimulant ( doxapram ) in antagonizing carbon dioxide retention associated with controlled oxygen therapy ( 28 per cent ) in acute-on-chronic respiratory failure was assessed by a double-blind crossover trial in eight patients .
C0013084
doxapram
C0020440
carbon